Find all
associated with


Refine your query (more in Advanced-Search):
 Focus on the recent 5 years   Focus on the current year   Focus on the last 30 days   More choices ...
 Focus on articles with free fulltexts   More choices ...
 Do simple 'keyword' search (no query expansion)

[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 10 of about 318890
1. Jain S, Sima DM, Sanaei Nezhad F, Hangel G, Bogner W, Williams S, Van Huffel S, Maes F, Smeets D: Patch-Based Super-Resolution of MR Spectroscopic Images: Application to Multiple Sclerosis. Front Neurosci; 2017;11:13

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patch-Based Super-Resolution of MR Spectroscopic Images: Application to Multiple Sclerosis.
  • <b>Purpose:</b> Magnetic resonance spectroscopic imaging (MRSI) provides complementary information to conventional magnetic resonance imaging.
  • The accuracy of the method is validated against conventional interpolation techniques using a phantom, as well as simulated and <i>in vivo</i> acquired human brain images of multiple sclerosis subjects.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biometrika. 1947;34(1-2):28-35 [20287819.001]
  • [Cites] J Magn Reson. 2016 Feb;263:193-208 [26766215.001]
  • [Cites] J Magn Reson. 1997 Dec;129(2):145-60 [9441879.001]
  • [Cites] Magn Reson Med. 2008 Apr;59(4):810-8 [18383297.001]
  • [Cites] Magn Reson Med. 2007 Feb;57(2):249-57 [17260356.001]
  • [Cites] Med Image Anal. 2010 Dec;14(6):784-92 [20566298.001]
  • [Cites] IEEE Trans Image Process. 2004 Apr;13(4):600-12 [15376593.001]
  • [Cites] Neuroimage. 2013 Dec;83:245-61 [23791914.001]
  • [Cites] Neuroimage Clin. 2015 May 16;8:367-75 [26106562.001]
  • [Cites] Magn Reson Med. 1995 Jan;33(1):34-40 [7891533.001]
  • [Cites] Magn Reson Med. 2002 Jun;47(6):1202-10 [12111967.001]
  • [Cites] IEEE Trans Med Imaging. 1991;10(2):132-7 [18222809.001]
  • [Cites] Magn Reson Med. 2011 Dec;66(6):1518-25 [21574181.001]
  • [Cites] IEEE Trans Med Imaging. 2007 Oct;26(10):1305-18 [17948722.001]
  • [Cites] IEEE Trans Med Imaging. 2007 May;26(5):686-95 [17518063.001]
  • [Cites] Magn Reson Med. 1998 Jun;39(6):889-98 [9621912.001]
  • [Cites] Magn Reson Med. 2017 Feb;77(2):467-479 [26841000.001]
  • [Cites] Neuroimage. 2016 Nov 4;:null [27825954.001]
  • [Cites] Neuroimage. 2014 Mar;88:22-31 [24201013.001]
  • [Cites] Magn Reson Med. 2007 Dec;58(6):1107-16 [17968995.001]
  • [Cites] Magn Reson Med. 1988 Nov;8(3):314-22 [3205158.001]
  • [Cites] Radiology. 2012 Feb;262(2):647-61 [22187628.001]
  • [Cites] Magn Reson Med. 1999 Nov;42(5):952-62 [10542355.001]
  • [Cites] J Magn Reson Imaging. 2013 Feb;37(2):445-56 [23011898.001]
  • [Cites] J Magn Reson Imaging. 2010 Apr;31(4):770-88 [20373420.001]
  • [Cites] Ther Adv Neurol Disord. 2013 Sep;6(5):298-310 [23997815.001]
  • [Cites] J Magn Reson Imaging. 2013 Jun;37(6):1301-25 [23188775.001]
  • [Cites] Neuroimage. 2015 Nov 1;121:126-35 [26210813.001]
  • [Cites] Int J Biomed Imaging. 2010;2010:425891 [21197094.001]
  • [Cites] Med Image Anal. 2010 Aug;14(4):594-605 [20580893.001]
  • [Cites] Neuroimaging Clin N Am. 2009 Feb;19(1):45-58 [19064199.001]
  • [Cites] NMR Biomed. 2015 Nov;28(11):1413-25 [26370781.001]
  • [Cites] Magn Reson Med. 2016 Aug 22;:null [27548836.001]
  • [Cites] Magn Reson Imaging. 2009 Dec;27(10):1319-25 [19577396.001]
  • [Cites] NMR Biomed. 2012 Jun;25(6):873-82 [22190245.001]
  • [Cites] Magn Reson Med. 2001 Oct;46(4):713-22 [11590648.001]
  • [Cites] IEEE Trans Med Imaging. 2007 Jul;26(7):990-1000 [17649912.001]
  • [Cites] Magn Reson Med. 2013 May;69(5):1217-25 [22692894.001]
  • [Cites] Magn Reson Med. 2015 Feb;73(2):469-80 [24585512.001]
  • [Cites] IEEE Trans Med Imaging. 2010 Jul;29(7):1333-50 [20304734.001]
  • [Cites] NMR Biomed. 2013 Dec;26(12):1796-805 [24038331.001]
  • (PMID = 28197066.001).
  • [ISSN] 1662-4548
  • [Journal-full-title] Frontiers in neuroscience
  • [ISO-abbreviation] Front Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Keywords] NOTNLM ; magnetic resonance spectroscopy imaging / multiple sclerosis / patch-based / super-resolution / up-sampling
  •  go-up   go-down


2. D'Cunha MA, Pandit L, Malli C: CD6 gene polymorphism rs17824933 is associated with multiple sclerosis in Indian population. Ann Indian Acad Neurol; 2016 Oct-Dec;19(4):491-494
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD6 gene polymorphism rs17824933 is associated with multiple sclerosis in Indian population.
  • BACKGROUND: Multiple sclerosis (MS) prevalence has increased worldwide.
  • The known genetic association for MS in the west has not been studied in detail in nonwhite populations and particularly Indians.
  • OBJECTIVE: The objective of this study was to evaluate some known genetic variations outside the major histocompatibility complex (MHC) region associated with MS in patients of Indian origin.
  • MATERIALS AND METHODS: We investigated 10 gene-associated single nucleotide polymorphisms (SNP's) outside the MHC region in 300 patients and 720 unrelated controls.
  • RESULTS: CD6 gene associated SNP (rs17824933) showed significant association with MS (<i>P</i> = 4.2 × 10<sup>-5</sup>, odds ratio [OR] = 2.24, confidence interval (CI) = 1.51-3.33).
  • CONCLUSION: Our data illustrate the similarity in risk association between Indian and European populations for MS.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2011 Aug 10;476(7359):214-9 [21833088.001]
  • [Cites] Mult Scler. 2012 Jul;18(7):959-65 [22194214.001]
  • [Cites] Lancet. 1996 Jun 22;347(9017):1728-30 [8656905.001]
  • [Cites] J Int Med Res. 2011;39(5):1625-35 [22117963.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Mar 31;106(13):5264-9 [19237575.001]
  • [Cites] Genes Immun. 2008 Oct;9(7):624-30 [18650830.001]
  • [Cites] Mult Scler. 2011 Feb;17(2):139-43 [20952449.001]
  • [Cites] Mult Scler. 2016 Jan;22(1):19-24 [25921049.001]
  • [Cites] J Neurol Sci. 2011 Dec 15;311(1-2):1-8 [21975017.001]
  • [Cites] J Neurol. 2007 May;254(5):682-4 [17420929.001]
  • [Cites] Ann Neurol. 2011 Feb;69(2):292-302 [21387374.001]
  • [Cites] PLoS One. 2013 Apr 24;8(4):e62376 [23638056.001]
  • [Cites] PLoS Genet. 2009 Jan;5(1):e1000322 [19119414.001]
  • [Cites] Lancet Neurol. 2014 Jul;13(7):700-9 [24852507.001]
  • [Cites] Eur J Hum Genet. 2009 Oct;17(10):1309-13 [19293837.001]
  • [Cites] J Hum Genet. 2009 Nov;54(11):676-80 [19834503.001]
  • [Cites] J Neuroimmunol. 2010 Jun;223(1-2):100-3 [20430450.001]
  • [Cites] Mult Scler. 2016 Oct;22(12 ):1536-1540 [26754803.001]
  • [Cites] PLoS One. 2011 Apr 28;6(4):e18813 [21552549.001]
  • [Cites] Brain. 2015 Jun;138(Pt 6):1518-30 [25818868.001]
  • [Cites] Lancet Neurol. 2008 Jul;7(7):567-9 [18565446.001]
  • [Cites] Nat Genet. 2013 Nov;45(11):1353-60 [24076602.001]
  • [Cites] Nat Genet. 2007 Sep;39(9):1083-91 [17660817.001]
  • [Cites] Hum Mol Genet. 2010 Mar 1;19(5):953-62 [20007504.001]
  • [Cites] Nat Genet. 2009 Jul;41(7):776-82 [19525953.001]
  • [Cites] Am J Hum Genet. 2007 Sep;81(3):559-75 [17701901.001]
  • [Cites] N Engl J Med. 2007 Aug 30;357(9):851-62 [17660530.001]
  • [Cites] Eur J Hum Genet. 2010 Apr;18(4):502-4 [19888296.001]
  • [Cites] Neurology. 2013 Jul 16;81(3):219-27 [23771490.001]
  • [Cites] Nature. 2009 Sep 24;461(7263):489-94 [19779445.001]
  • [Cites] Neurol India. 2012 Sep-Oct;60(5):470-5 [23135022.001]
  • (PMID = 27994359.001).
  • [ISSN] 0972-2327
  • [Journal-full-title] Annals of Indian Academy of Neurology
  • [ISO-abbreviation] Ann Indian Acad Neurol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Keywords] NOTNLM ; Genetic susceptibility / Indian / South Asians / multiple sclerosis / single nucleotide polymorphism
  •  go-up   go-down


3. Fewings N, Gatt PN, McKay FC, Parnell GP, Schibeci SD, Edwards J, Basuki MA, Goldinger A, Fabis-Pedrini MJ, Kermode AG, Manrique CP, McCauley JL, Nickles D, Baranzini SE, Burke T, Vucic S, Stewart GJ, Booth DR: Data characterizing the ZMIZ1 molecular phenotype of multiple sclerosis. Data Brief; 2017 Apr;11:364-370
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Data characterizing the ZMIZ1 molecular phenotype of multiple sclerosis.
  • The data presented in this article are related to the research article entitled "The autoimmune risk gene ZMIZ1 is a vitamin D responsived marker of a molecular phenotype of multiple sclerosis" Fewings et al. (2017) [1].
  • Here we identify the set of genes correlated with ZMIZ1 in multiple cohorts, provide phenotypic details on those cohorts, and identify the genes negatively correlated with ZMIZ1 and the cells predominantly expressing those genes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2011 Aug 10;476(7359):214-9 [21833088.001]
  • [Cites] Hum Mol Genet. 2014 Mar 15;23 (6):1425-34 [24158849.001]
  • [Cites] Hum Mol Genet. 2013 Oct 15;22(20):4194-205 [23748426.001]
  • [Cites] Ann Neurol. 2011 Feb;69(2):292-302 [21387374.001]
  • [Cites] Clin Immunol. 2016 Feb;163:96-107 [26762769.001]
  • [Cites] J Autoimmun. 2017 Mar;78:57-69 [28063629.001]
  • [Cites] Clin Immunol. 2014 Mar;151(1):16-24 [24495857.001]
  • [Cites] Ann Neurol. 2011 Dec;70(6):881-6 [22190362.001]
  • [Cites] Hum Mol Genet. 2010 Jun 1;19(11):2134-43 [20190274.001]
  • [Cites] Nat Genet. 2013 Nov;45(11):1353-60 [24076602.001]
  • [Cites] Mult Scler. 2014 May;20(6):675-85 [24126065.001]
  • (PMID = 28275670.001).
  • [ISSN] 2352-3409
  • [Journal-full-title] Data in brief
  • [ISO-abbreviation] Data Brief
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS088155
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Keywords] NOTNLM ; Gene expression / Molecular phenotype / Multiple sclerosis / ZMIZ1
  •  go-up   go-down


Advertisement
4. Qendro V, Bugos GA, Lundgren DH, Glynn J, Han MH, Han DK: Integrative proteomics, genomics, and translational immunology approaches reveal mutated forms of Proteolipid Protein 1 (PLP1) and mutant-specific immune response in multiple sclerosis. Proteomics; 2017 Mar;17(6)
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Integrative proteomics, genomics, and translational immunology approaches reveal mutated forms of Proteolipid Protein 1 (PLP1) and mutant-specific immune response in multiple sclerosis.
  • In order to gain mechanistic insights into multiple sclerosis (MS) pathogenesis, we utilized a multi-dimensional approach to test the hypothesis that mutations in myelin proteins lead to immune activation and central nervous system autoimmunity in MS.
  • Mass spectrometry-based proteomic analysis of human MS brain lesions revealed seven unique mutations of PLP1; a key myelin protein that is known to be destroyed in MS.
  • Surprisingly, in-depth genomic analysis of two MS patients at the genomic DNA and mRNA confirmed mutated PLP1 in RNA, but not in the genomic DNA.
  • Quantification of wild type and mutant PLP RNA levels by qPCR further validated the presence of mutant PLP RNA in the MS patients.
  • To seek evidence linking mutations in abundant myelin proteins and immune-mediated destruction of myelin, specific immune response against mutant PLP1 in MS patients was examined.
  • Thus, we have designed paired, wild type and mutant peptide microarrays, and examined antibody response to multiple mutated PLP1 in sera from MS patients.
  • Consistent with the idea of different patients exhibiting unique mutation profiles, we found that 13 out of 20 MS patients showed antibody responses against specific but not against all the mutant-PLP1 peptides.
  • Interestingly, we found mutant PLP-directed antibody response against specific mutant peptides in the sera of pre-MS controls.
  • The results from integrative proteomic, genomic, and immune analyses reveal a possible mechanism of mutation-driven pathogenesis in human MS.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
  • (PMID = 28191734.001).
  • [ISSN] 1615-9861
  • [Journal-full-title] Proteomics
  • [ISO-abbreviation] Proteomics
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Keywords] NOTNLM ; Genomics / Immunoproteomics / Multiple sclerosis / Next generation sequencing / PLP1 / Peptide microarrays / Precision / Proteomics
  •  go-up   go-down


5. Haibing X, Xu C, Jifu C, Wenshuang Z, Ling L, Yuzhen C, Yanjun H: Correlation between CTLA-4 gene rs221775A&gt;G single nucleotide polymorphism and multiple sclerosis susceptibility. A meta-analysis. Open Med (Wars); 2016;11(1):264-269

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation between CTLA-4 gene rs221775A>G single nucleotide polymorphism and multiple sclerosis susceptibility. A meta-analysis.
  • OBJECTIVE: The aim of this meta-analysis was to undertake a meta-analysis to evaluate the correlation between cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) gene rs221775 A>G single nucleotide polymorphism and the susceptibility of multiple sclerosis (MS) susceptibility.
  • METHOD: Published manuscripts about CTLA-4 gene rs221775A>G single nucleotide polymorphism and multiple sclerosis susceptibility were searched in the computerized bibliographic searches of Pubmed Embase and China National Knowledge Infrastructure (CNKI).
  • Potential studies were screened and data for 5025 MS patients and 4706 controls from 20 publications were included.
  • The association between CTLA-4 gene rs221775A>G single nucleotide polymorphism and multiple sclerosis susceptibility were demonstrated by odds ratio (OR) and 95% confidence interval (95%CI).
  • RESULTS: The pooled results showed no significant association between CTLA-4 gene rs221775A>G single nucleotide polymorphism and multiple sclerosis susceptibility for dominant genetic model [OR=1.02, 95%CI:0.90~1.05, (P=0.80)], homozygous genetic model [OR=0.85,95%CI:0.71 ~1.03,(P=0.10)] and recessive genetic model [OR=0.99,95% CI:0.89~1.10,(P=0.90)].
  • CONCLUSION: With current evidence, CTLA-4 gene rs221775A>G single nucleotide polymorphism had no association with the susceptibility of multiple sclerosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neuroimmunol. 2005 Sep;166(1-2):197-201 [16005527.001]
  • [Cites] J Neuroimmunol. 2002 Oct;131(1-2):213-5 [12458055.001]
  • [Cites] Iran J Allergy Asthma Immunol. 2010 Dec;9(4):219-23 [21131701.001]
  • [Cites] Exp Mol Pathol. 2005 Feb;78(1):55-7 [15596061.001]
  • [Cites] Int J Immunogenet. 2011 Oct;38(5):419-26 [21797987.001]
  • [Cites] Lancet Neurol. 2009 Jan;8(1):6-8 [19081501.001]
  • [Cites] Acta Neurol Scand Suppl. 2011;(191):44-9 [21711256.001]
  • [Cites] J Neuroimmunol. 2005 Feb;159(1-2):225-9 [15652423.001]
  • [Cites] J Neuroimmunol. 2003 Jul;140(1-2):188-93 [12864988.001]
  • [Cites] J Neuroimmunol. 2003 Jan;134(1-2):133-41 [12507781.001]
  • [Cites] J Neuroimmunol. 2007 Jul;187(1-2):187-91 [17524498.001]
  • [Cites] Acta Neurol Scand. 2009 Dec;120(6):424-9 [19737153.001]
  • [Cites] J Neuroimmunol. 2004 Mar;148(1-2):218-30 [14975605.001]
  • [Cites] Mult Scler. 2008 Mar;14(2):153-8 [17942509.001]
  • [Cites] BMJ. 2003 Sep 6;327(7414):557-60 [12958120.001]
  • [Cites] J Neuroimmunol. 2002 Oct;131(1-2):208-12 [12458054.001]
  • [Cites] Immunity. 1997 Dec;7(6):885-95 [9430233.001]
  • [Cites] J Neurol Sci. 2001 Mar 1;184(2):143-7 [11239948.001]
  • [Cites] J Neuroimmunol. 2008 May 30;196(1-2):139-42 [18378005.001]
  • [Cites] J Neuroimmunol. 2006 Aug;177(1-2):146-50 [16769128.001]
  • [Cites] Mult Scler. 2011 Oct;17(10):1171-3 [21980150.001]
  • [Cites] Ann Neurol. 2003 Jul;54(1):119-22 [12838528.001]
  • [Cites] Acta Neurol Scand. 2004 Jul;110(1):67-71 [15180809.001]
  • [Cites] Arch Immunol Ther Exp (Warsz). 2003;51(3):201-5 [12894875.001]
  • [Cites] Mol Biol (Mosk). 2002 Jul-Aug;36(4):643-8 [12173468.001]
  • [Cites] J Neuroimmunol. 1999 Jun 1;97(1-2):182-90 [10408973.001]
  • (PMID = 28352806.001).
  • [ISSN] 2391-5463
  • [Journal-full-title] Open medicine (Warsaw, Poland)
  • [ISO-abbreviation] Open Med (Wars)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Keywords] NOTNLM ; CTLA-4 gene / Meta-analysis / Multiple sclerosis / Polymorphism / Susceptibility
  •  go-up   go-down


6. Gromisch ES, Schairer LC, Pasternak E, Kim SH, Foley FW: Assessment and Treatment of Psychiatric Distress, Sexual Dysfunction, Sleep Disturbances, and Pain in Multiple Sclerosis: A Survey of Members of the Consortium of Multiple Sclerosis Centers. Int J MS Care; 2016 Nov-Dec;18(6):291-297

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment and Treatment of Psychiatric Distress, Sexual Dysfunction, Sleep Disturbances, and Pain in Multiple Sclerosis: A Survey of Members of the Consortium of Multiple Sclerosis Centers.
  • : <b>Background:</b> Psychiatric distress (depression and anxiety), sexual dysfunction, sleep disturbances, and pain are frequent comorbidities in multiple sclerosis (MS) that have the potential to interfere with functioning and quality of life.
  • To better understand current practices, this study aimed to gain a multidisciplinary perspective on how MS providers assess and treat these five problems.
  • <b>Methods:</b> An online questionnaire was completed by 42 members of the Consortium of Multiple Sclerosis Centers on their assessment procedures, treatment recommendations, and prevalence rates of these issues in their practices.
  • <b>Conclusions:</b> Health-care providers are aware of the prevalence of these issues in their patients with MS.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27999523.001).
  • [ISSN] 1537-2073
  • [Journal-full-title] International journal of MS care
  • [ISO-abbreviation] Int J MS Care
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Zare L, Sheikh Fathollahi M, Kazemi Arababadi M, Shamsizadeh A, Daneshpajouh B, Zainodini N, Allahtavakoli M: The Association Between C424c/A Polymorphism Within the IL-25 Gene and Multiple Sclerosis. Iran Red Crescent Med J; 2016 Sep;18(9):e25995

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Association Between C424c/A Polymorphism Within the IL-25 Gene and Multiple Sclerosis.
  • BACKGROUND: Multiple Sclerosis (MS) is a common autoimmune system disease which affects the central nervous system.
  • It has been documented that interleukin-25 (IL-25) plays key roles in suppressing Th1 responses, which is increased during MS.
  • OBJECTIVES: The aim of this study was to investigate the c424C/A polymorphism within the IL-25 gene in MS patients in comparison to healthy controls.
  • PATIENTS AND METHODS: In this case-control study, 74 patients with MS and 75 healthy controls were selected.
  • Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP) was used in order to determine c424C/A polymorphism within the IL-25 gene.
  • RESULTS: The results showed that there was no statistical significant difference in distribution of genotype (AA, AC and CC) and allele (A and C) frequencies between MS patients and healthy controls (P = 0.901 and P = 0.728, respectively).
  • CONCLUSIONS: In conclusion, it appears that the c424C/A polymorphism within the IL-25 gene has no significant relationship with MS, and this polymorphism is probably not associated with MS complications, its onset and gender distribution.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Exp Immunol. 2014 Aug 15;3(2):91-6 [25143869.001]
  • [Cites] Nature. 2011 Aug 10;476(7359):214-9 [21833088.001]
  • [Cites] Ann Neurol. 2001 Jul;50(1):121-7 [11456302.001]
  • [Cites] Eur Arch Psychiatry Clin Neurosci. 2013 Nov;263 Suppl 2:S123-36 [24077889.001]
  • [Cites] Immunology. 2008 Oct;125(2):161-9 [18397264.001]
  • [Cites] Immunity. 2001 Dec;15(6):985-95 [11754819.001]
  • [Cites] Iran Red Crescent Med J. 2014 Jun;16(6):e17173 [25068045.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2009 Apr;80(4):386-91 [18931003.001]
  • [Cites] Brain. 2014 Mar;137(Pt 3):770-8 [24441172.001]
  • [Cites] Inflammation. 2012 Jun;35(3):797-802 [21909800.001]
  • [Cites] Mult Scler. 2002 Apr;8(2):115-8 [11990867.001]
  • [Cites] Neurology. 1991 May;41(5):685-91 [2027484.001]
  • [Cites] Iran J Radiol. 2013 Sep;10(3):128-32 [24348597.001]
  • [Cites] Ann Neurol. 2007 Apr;61(4):288-99 [17444504.001]
  • [Cites] Eur J Immunogenet. 2003 Oct;30(5):329-33 [14641539.001]
  • [Cites] Lancet. 2003 Feb 15;361(9357):545-52 [12598138.001]
  • (PMID = 28144453.001).
  • [ISSN] 2074-1804
  • [Journal-full-title] Iranian Red Crescent medical journal
  • [ISO-abbreviation] Iran Red Crescent Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Iran
  • [Keywords] NOTNLM ; CCL25 / Genetic / Multiple Sclerosis / Polymorphism
  •  go-up   go-down


8. Muto M, Mori M, Liu J, Uzawa A, Uchida T, Masuda H, Ohtani R, Sugimoto K, Kuwabara S: Serum soluble Talin-1 levels are elevated in patients with multiple sclerosis, reflecting its disease activity. J Neuroimmunol; 2017 Apr 15;305:131-134

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum soluble Talin-1 levels are elevated in patients with multiple sclerosis, reflecting its disease activity.
  • Previously, we identified anti-Talin-1 antibodies in the serum of MS.
  • In this case, we measured the serum soluble Talin-1 (sTalin-1) levels by enzyme-linked immunosorbent assay.
  • The serum sTalin-1 levels were significantly higher in 40 patients with MS than in 43 normal controls and in the acute phase of disease than in the remission phase.
  • Interestingly, serum sTalin-1 levels were associated with a sustained increase in disability after MS attack but not with serum anti-Talin-1 antibody levels. sTalin-1 may be a biomarker for the acute phase of MS and may be used for the short-term prognosis of MS.
  • [MeSH-major] Multiple Sclerosis, Relapsing-Remitting / blood. Talin / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier B.V. All rights reserved.
  • (PMID = 28284333.001).
  • [ISSN] 1872-8421
  • [Journal-full-title] Journal of neuroimmunology
  • [ISO-abbreviation] J. Neuroimmunol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies; 0 / TLN1 protein, human; 0 / Talin
  • [Keywords] NOTNLM ; Multiple sclerosis / SEREX / Soluble Talin-1 / Talin-1 protein / anti-Talin-1 antibody
  •  go-up   go-down


9. Jazaeri A, Vallian S: Association of rs1738074 polymorphism of TAGAP gene with susceptibility to multiple sclerosis in the Iranian population. Neurosci Lett; 2017 May 01;648:66-69

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of rs1738074 polymorphism of TAGAP gene with susceptibility to multiple sclerosis in the Iranian population.
  • Multiple sclerosis (MS) is one of the most common diseases of the central nervous system (CNS) in the Iranian population.
  • To date, association of many genes with the prevalence and progression of the disease have been investigated.
  • In the present study, the impact of rs1738074 single nucleotide polymorphism (SNP) in the TAGAP gene (TAGAP rs1738074) on the risk of MS was evaluated in a sample of the Iranian population.
  • Interestingly, individuals with T/T genotype were estimated to be less susceptible to MS ((p-value=0.025), Fisher's exact test), odd ratio was 2.18 (controls versus MS patients) with 95% CI: 1.137-4.187.
  • The results suggested that TAGAP rs1738074 polymorphism could be considered as a risk factor in the prevalence of MS in the Iranian population.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier B.V. All rights reserved.
  • (PMID = 28356229.001).
  • [ISSN] 1872-7972
  • [Journal-full-title] Neuroscience letters
  • [ISO-abbreviation] Neurosci. Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Keywords] NOTNLM ; Iranian population / Multiple sclerosis / Polymorphic markers / TAGAP gene
  •  go-up   go-down


10. Buhelt S, Ratzer RL, Christensen JR, Börnsen L, Sellebjerg F, Søndergaard HB: Relationship between soluble CD25 and gene expression in healthy individuals and patients with multiple sclerosis. Cytokine; 2017 May;93:15-25
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship between soluble CD25 and gene expression in healthy individuals and patients with multiple sclerosis.
  • Genome wide association studies and fine mapping has established a firm link between the IL2RA gene, encoding the interleukin-2 receptor α-chain CD25, and susceptibility to multiple sclerosis (MS).
  • We hypothesized that gene expression in peripheral blood mononuclear cells (PBMCs) from healthy controls (HCs) and MS patients are associated with IL2RA SNP rs2104286 and that gene expression levels correlate with soluble CD25 (sCD25) concentrations - that are affected by rs2104286.
  • We used the Affymetrix Human Gene ST 1.0 microarray to analyze gene expression levels in PBMCs from 18 HCs and 51MS patients.
  • In HCs 266 genes correlated with sCD25 with Spearman's rho≥0.707; 70 of these genes had a false discovery rate (FDR) value of q<0.05.
  • Gene-networks were focused around NFKB1, TNF, BCL6 and STAT1.
  • Eighteen genes correlated with sCD25 with rho≥0.707 in relapsing remitting MS versus 33 in secondary progressive and 34 in primary progressive MS.
  • Thirty-eight and 23 genes were differentially expressed between rs2104286 genotype-groups in MS patients and HCs respectively, however they were not significant after FDR correction.
  • Our study indicates that rs2104286 influences gene expression in PBMCs in HCs as shown by the high correlations with the rs2104286-affected sCD25 protein.
  • Correlations were strongest in HCs suggesting that immunological alterations may obscure the role of the IL2RA SNP rs2104286 in established MS.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier Ltd. All rights reserved.
  • (PMID = 28511943.001).
  • [ISSN] 1096-0023
  • [Journal-full-title] Cytokine
  • [ISO-abbreviation] Cytokine
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; IL2RA / Multiple sclerosis / rs2104286 / sCD25
  •  go-up   go-down






Advertisement